Core Viewpoint - Analysts project that BioMarin Pharmaceutical (BMRN) will report quarterly earnings of $0.57 per share, reflecting a 5.6% year-over-year increase, with revenues expected to reach $660.51 million, an 11% increase from the same quarter last year [1]. Revenue Estimates - The consensus for 'Revenues- Net product revenues' is projected at $648.62 million, indicating a 10.9% increase from the prior-year quarter [3]. - 'Revenues- Net Product Revenues- ALDURAZYME' is expected to be $35.01 million, showing a year-over-year decline of 13.1% [4]. - 'Revenues- Net Product Revenues- PALYNZIQ' is forecasted at $81.13 million, reflecting an 8.3% increase from the previous year [5]. - 'Revenues- Net Product Revenues- NAGLAZYME' is estimated at $106.25 million, indicating a 17.9% year-over-year increase [6]. - 'Revenues- Royalty and other revenues' is projected to be $11.90 million, representing a 12.5% increase year-over-year [9]. - 'Revenues- Net Product Revenues- BRINEURA' is expected to reach $42.14 million, indicating a 10.6% year-over-year increase [10]. - 'Revenues- Net Product Revenues- KUVAN' is forecasted at $31.18 million, reflecting a significant decline of 38.4% year-over-year [11]. - 'Revenues- Net Product Revenues- VIMIZIM' is projected to be $183.06 million, showing a 3.2% increase from the year-ago quarter [12]. - 'Revenues- Net Product Revenues- VOXZOGO' is expected to arrive at $165.51 million, indicating a substantial 46.1% increase from the previous year [13]. Stock Performance - BioMarin shares have increased by 2.6% over the past month, contrasting with the Zacks S&P 500 composite's decline of 0.4%, and the stock holds a Zacks Rank 3 (Hold), suggesting it will closely follow overall market performance [7].

Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show Symptoms The sBLA is supported by data from Study 190-203, a Phase 2, open-label, multicenter trial evaluating BRINEURA treatment over the span of approximately three years in children aged 1-6 years at baseline, including eight children less than 3 years of age. Results from Study 190-203, which were presented at the 20th Annual We're Organizing Research on Lysosomal Diseases meeting (WORLDSymposium) in Febr ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering BioMarin Pharmaceutical (BMRN) , which belongs to the Zacks Medical - Biomedical and Genetics industry. For the last reported quarter, BioMarin came out with earnings of $0.71 per share versus the Zacks Consensus Estimate of $0.60 per share, representing a surprise of 18.33%. For the previous quarter, the company was expected to post earnings of $0.44 per sha ...

SAN RAFAEL, Calif., July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 5, 2024, at 4:30 p.m. ET to discuss second quarter 2024 financial results and provide a general business update. Contacts: Investors Media Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc.BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 Dial-in Number U.S ...

Company Overview - BioMarin Pharmaceutical (BMRN) is expected to report a year-over-year increase in earnings, with a projected quarterly earnings per share (EPS) of $0.56, reflecting a change of +3.7% [3] - Revenues are anticipated to reach $659.73 million, representing a 10.8% increase from the same quarter last year [4] Earnings Expectations - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [5] - The Most Accurate Estimate for BioMarin is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -13.67%, suggesting a bearish outlook from analysts [11] Historical Performance - In the last reported quarter, BioMarin exceeded expectations by posting earnings of $0.71 per share against an expected $0.60, achieving a surprise of +18.33% [14] - Over the past four quarters, the company has beaten consensus EPS estimates three times [15] Industry Comparison - Bristol Myers Squibb (BMY), another player in the biomedical industry, is expected to report an EPS of $1.64 for the same quarter, indicating a year-over-year decline of -6.3% [19] - Bristol Myers' revenues are projected to be $11.5 billion, up 2.5% from the previous year [19] - The consensus EPS estimate for Bristol Myers has been revised 1% lower in the last 30 days, resulting in an Earnings ESP of -0.15% [20]

Investors in BioMarin Pharmaceutical (BMRN) need to pay close attention to the stock based on moves in the options market lately. That is because the Sept 20, 2024 $40.00 Call had some of the highest implied volatility of all equity options today. What do the Analysts Think? Given the way analysts feel about BioMarin Pharmaceutical right now, this huge implied volatility could mean there's a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium ...

SAN RAFAEL, Calif., May 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President, and Chief Executive Officer of BioMarin will present at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 10:00am PT / 1:00pm ET, in Las Vegas, Nevada. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through ...

As we near the end of the ongoing reporting cycle in the biotech sector, the picture is pretty ho-hum. The bigwigs in the sector have already reported and the results have been mostly mixed. Nonetheless, the outlook provided by most of these companies is encouraging, indicating bright prospects driven by new drug approvals and positive pipeline updates. The macroeconomic environment, however, remains uncertain and growth might be sluggish.Nonetheless, companies in this volatile biotech industry continue to ...

Investigator-Sponsored Phase 2 Study Demonstrated Positive Results in Children with Noonan Syndrome, Idiopathic Short Stature and Other Growth-Related Conditions BioMarin-Sponsored Phase 3 Data Show Notable Mean Annualized Growth Velocity Increases in Children with Achondroplasia Who Started Treatment During Adolescence SAN RAFAEL, Calif., May 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in ch ...

| --- | --- | |-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...